AlloVir (ALVR) Competitors $6.70 +0.24 (+3.72%) As of 04/16/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. PBYI, KRRO, CTNM, RAPT, TNGX, TARA, ACTU, LYEL, GLSI, and IKTShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Puma Biotechnology (PBYI), Korro Bio (KRRO), Contineum Therapeutics (CTNM), RAPT Therapeutics (RAPT), Tango Therapeutics (TNGX), Protara Therapeutics (TARA), Actuate Therapeutics (ACTU), Lyell Immunopharma (LYEL), Greenwich LifeSciences (GLSI), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Puma Biotechnology Korro Bio Contineum Therapeutics RAPT Therapeutics Tango Therapeutics Protara Therapeutics Actuate Therapeutics Lyell Immunopharma Greenwich LifeSciences Inhibikase Therapeutics AlloVir (NASDAQ:ALVR) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability. Does the MarketBeat Community prefer ALVR or PBYI? Puma Biotechnology received 528 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 67.27% of users gave Puma Biotechnology an outperform vote while only 57.45% of users gave AlloVir an outperform vote. CompanyUnderperformOutperformAlloVirOutperform Votes2757.45% Underperform Votes2042.55% Puma BiotechnologyOutperform Votes55567.27% Underperform Votes27032.73% Which has more volatility and risk, ALVR or PBYI? AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Do analysts recommend ALVR or PBYI? Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 144.33%. Given Puma Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Puma Biotechnology is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ALVR or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to AlloVir's net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% Puma Biotechnology 9.56%41.60%10.71% Do institutionals and insiders hold more shares of ALVR or PBYI? 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, ALVR or PBYI? Puma Biotechnology has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.32Puma Biotechnology$230.47M0.62$21.59M$0.614.70 Does the media prefer ALVR or PBYI? In the previous week, Puma Biotechnology had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for Puma Biotechnology and 0 mentions for AlloVir. Puma Biotechnology's average media sentiment score of 0.92 beat AlloVir's score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment AlloVir Neutral Puma Biotechnology Positive SummaryPuma Biotechnology beats AlloVir on 15 of the 17 factors compared between the two stocks. Remove Ads Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.58M$2.82B$5.27B$7.32BDividend YieldN/A1.87%5.11%4.31%P/E Ratio-0.3230.3921.6617.68Price / SalesN/A431.61377.2292.80Price / CashN/A168.6838.1534.64Price / Book0.223.386.363.94Net Income-$190.42M-$72.06M$3.20B$247.45M7 Day Performance-16.21%4.36%4.07%3.32%1 Month Performance-33.13%-18.93%-10.26%-8.51%1 Year Performance-62.89%-29.05%10.36%0.66% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$6.70+3.7%N/A-61.8%$33.79MN/A-0.33110Gap UpHigh Trading VolumePBYIPuma Biotechnology3.5321 of 5 stars$2.83-2.4%$7.00+147.3%-43.5%$140.40M$230.47M5.90200Analyst UpgradeNews CoverageKRROKorro Bio1.5308 of 5 stars$14.93+3.8%$136.33+813.2%-81.7%$140.18M$2.27M-1.5970Analyst ForecastNews CoverageGap DownCTNMContineum Therapeutics2.1632 of 5 stars$5.37-7.4%$24.80+361.8%-71.8%$138.93M$50M-1.1031Positive NewsGap DownRAPTRAPT Therapeutics3.6594 of 5 stars$1.05-0.9%$4.00+281.0%-90.1%$138.61M$1.53M-0.3880Short Interest ↑News CoverageTNGXTango Therapeutics1.9385 of 5 stars$1.27flat$12.33+871.1%-82.6%$137.30M$42.07M-1.0890Analyst ForecastAnalyst RevisionNews CoverageTARAProtara Therapeutics1.8394 of 5 stars$3.70-5.1%$22.50+508.1%+40.4%$136.04MN/A-1.3130Analyst ForecastNews CoverageGap DownACTUActuate TherapeuticsN/A$6.82-1.0%$20.00+193.3%N/A$133.21MN/A0.0010News CoverageLYELLyell Immunopharma3.2115 of 5 stars$0.45-3.9%$1.00+123.9%-81.8%$131.85M$61,000.00-0.57270Analyst ForecastNews CoverageGap DownGLSIGreenwich LifeSciences1.9505 of 5 stars$9.59+8.6%$38.00+296.2%-38.7%$126.06MN/A-11.993Earnings ReportUpcoming EarningsGap DownHigh Trading VolumeIKTInhibikase Therapeutics1.4382 of 5 stars$1.68-8.7%$6.50+286.9%-8.3%$124.90M$260,000.00-0.636 Remove Ads Related Companies and Tools Related Companies PBYI Alternatives KRRO Alternatives CTNM Alternatives RAPT Alternatives TNGX Alternatives TARA Alternatives ACTU Alternatives LYEL Alternatives GLSI Alternatives IKT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALVR Stock Free ALVR Stock Alerts